Frankfurt
13.06.25 | 21:46
0,190 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.06. | NICOX SA: Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative | 4 | GlobeNewswire (USA) | ||
| 27.05. | NICOX SA: Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan | 586 | GlobeNewswire (Europe) | Press Release Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
Exclusive Japanese partner Kowa has received... ► Artikel lesen | |
| 14.05. | Nicox Reports Positive Phase 3b Trial Results For NCX 470 In Intraocular Pressure Reduction | 2 | RTTNews | ||
| 14.05. | NICOX SA: Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial | 294 | GlobeNewswire (Europe) | Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended... ► Artikel lesen | |
| 30.04. | Nicox reports FY results | 1 | Seeking Alpha | ||
| NICOX Aktie jetzt für 0€ handeln | |||||
| 30.04. | NICOX SA: Nicox Provides Full Year 2024 Financial Results | 247 | GlobeNewswire (Europe) | Press Release Nicox Provides Full Year 2024 Financial Results
Nicox SA revenue of €7.9 million for full year 2024 Exceptional income of €13.7 million following the transfer of VYZULTA's future... ► Artikel lesen | |
| 19.03. | NICOX SA: Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial | 424 | GlobeNewswire (Europe) | Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali... ► Artikel lesen | |
| 06.03. | NICOX SA: Nicox Extends Cash Runway into Q4 2025 | 725 | GlobeNewswire (Europe) | Press Release Nicox Extends Cash Runway into Q4 2025
Flexible equity financing line with Vester Finance of up to 10,000,000 shares over 24 monthsImmediate upfront payment from Vester Finance... ► Artikel lesen | |
| 03.03. | NICOX SA: Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update | 451 | GlobeNewswire (Europe) | Press Release Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal... ► Artikel lesen | |
| 28.01. | NICOX SA: Nicox Announces Scientific Presentation and Conference Attendance in H1 2025 | 339 | GlobeNewswire (Europe) | Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025January 28, 2025 - release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124... ► Artikel lesen | |
| 21.01. | NICOX SA: Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights | 478 | GlobeNewswire (Europe) | Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights
Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline... ► Artikel lesen | |
| 04.12.24 | NICOX SA: Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream | 579 | GlobeNewswire (Europe) | Press Release Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream
First commercialized product from the Nicox-Ocumension... ► Artikel lesen | |
| 02.12.24 | NICOX SA: Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected | 433 | GlobeNewswire (Europe) | Press ReleaseNicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected
Confirms topline results expected to be reported Q3 2025
NCX 470 demonstrated robust... ► Artikel lesen | |
| 19.11.24 | NICOX SA: Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial | 444 | GlobeNewswire (Europe) | Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial
An adaptive design is a useful clinical trial design tool which allowed identification... ► Artikel lesen | |
| 17.10.24 | NICOX SA: Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results | 376 | GlobeNewswire (Europe) | Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results
Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3... ► Artikel lesen | |
| 14.10.24 | NICOX SA: Nicox and Soleus Sign $16.5 million Royalty and Equity Financing | 370 | GlobeNewswire (Europe) | Press Release
Nicox and Soleus Sign $16.5 million Royalty and Equity Financing
Gross proceeds of $15 million (€13.7 million) for the sale of Nicox's net share of the VYZULTA royalty to SoleusSoleus... ► Artikel lesen | |
| 23.09.24 | NICOX SA: Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement | 567 | GlobeNewswire (Europe) | Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including... ► Artikel lesen | |
| 18.09.24 | NICOX SA: Nicox Announces Approval of ZERVIATE in China | 421 | GlobeNewswire (Europe) | Press Release Nicox Announces Approval of ZERVIATE in China
Nicox's partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China ZERVIATE® launch in China... ► Artikel lesen | |
| 04.09.24 | NICOX SA: Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board | 554 | GlobeNewswire (Europe) | Press Release Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board
Christine Placet is CFO of Theranexus, and was formerly CEO of Horama and TrophosMichele... ► Artikel lesen | |
| 25.07.24 | NICOX SA: Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 | 366 | GlobeNewswire (Europe) | Press Release Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470
Recruitment continues in China, on track for topline results in H2 2025 NCX 470 demonstrated... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 27,480 | -1,22 % | BioNTech-Milliarden-Deal Vorlage für BioNxt Solutions? Bayer-Aktie mit Kaufempfehlung! | Der Milliarden-Deal von BioNTech und Bristol-Myers Squibb war ein echter Paukenschlag und hat die Biotech-Branche wieder wach geküsst. Während Analysten ihr Kursziel für den deutschen Biotech-Überflieger... ► Artikel lesen | |
| NOVO NORDISK | 69,14 | +0,17 % | Novo Nordisk: Aktie zieht weiter an - gelingt jetzt der Ausbruch? | Die Aktie von Novo Nordisk kann ihre jüngst gestartete Erholungsbewegung auch am heutigen Montag fortsetzen. Auf der Handelplattform Tradegate gewinnt das Papier derzeit gut ein Prozent. Damit nähert... ► Artikel lesen | |
| PFIZER | 21,190 | -0,21 % | Massive Veränderung voraus? Hims & Hers Health, Novartis, PanGenomic Health, Pfizer | Mit einem Paukenschlag wartete Anfang der Woche der US-Gesundheitsminister Robert Kennedy auf. Der Kritiker an dem massiven Anstieg der Impfhäufigkeit in den letzten 40 Jahren in den USA gab bekannt... ► Artikel lesen | |
| MERCK KGAA | 114,80 | -1,42 % | EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Merck KGaA
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| GILEAD SCIENCES | 95,00 | -0,24 % | Dividendenbekanntmachungen (13.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 2G ENERGY AG DE000A0HL8N9 - 0,2 EUR ADANI PORTS AND SPECIAL ECONOMIC ZONE LT ... INE742F01042 7 INR 0,0705 EUR ALBEMARLE CORPORATION US0126531013 0... ► Artikel lesen | |
| SANOFI | 85,99 | -0,03 % | Sanofi SA-Aktie: Kurs fällt ab (87,82 €) | Im Minus liegt aktuell das Wertpapier von Sanofi SA . Die Aktie kostete zuletzt 87,82 Euro. Die Aktie von Sanofi SA verzeichnet derzeit einen Kursrückgang von 1,44 Prozent. Sie hat sich um 1,28 Euro... ► Artikel lesen | |
| GSK | 17,885 | -2,27 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK mit einem Kursziel von 1460 Pence auf "Underweight" belassen. Ein Gespräch mit einem Experten auf dem Gebiet des Multiplen... ► Artikel lesen | |
| ELI LILLY | 711,00 | +0,58 % | Dividendenbekanntmachungen (10.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGNC INVESTMENT CORP US00123Q1040 0,12 USD EUR AKER CARBON CAPTURE ASA NO0010890304 2,86 NOK 0,2487 EUR AMEREN CORPORATION US0236081024 0... ► Artikel lesen | |
| MERCK & CO | 70,80 | 0,00 % | Pille statt Spritze!: Gamechanger Enlicitid - Ist der Abwärtstrend bei Merck & Co. endlich gestoppt? | © Foto: © 2023 Merck & CoDie Aktie von Merck hat eine lange Durststrecke hinter sich. Vor etwas mehr als einem Jahr stand der Kurs noch bei rund 134 US-Dollar. Mittlerweile ist die Aktie nur noch rund... ► Artikel lesen | |
| HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
| TEVA | 14,650 | -0,34 % | Teva Pharmaceutical: Teva Honored With Power of Partnership Award for Global Health Impact | NORTHAMPTON, MA / ACCESS Newswire / June 10, 2025 / Teva Pharmaceuticals has been recognized with the 2025 Power of Partnership Award by Americares, in collaboration with the Healthcare Distribution... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 397,55 | +0,77 % | Vertex lays off 125 staffers, slims Rhode Island campus after ditching failed diabetes cell-device combo | ||
| ABBOTT LABORATORIES | 118,38 | +0,56 % | Abbott Declares 406th Consecutive Quarterly Dividend | ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
This... ► Artikel lesen | |
| BIOTEST | 29,600 | -0,67 % | Grifols' takeover bid for Biotest, accepted by 2.11% of ordinary shares with voting rights (1.05% of capital) | ||
| DOCMORRIS | 7,390 | -0,07 % | Nach Erfolg über Doc Morris: Kammer will weiter gegen Versender vorgehen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NICOX SA finden Sie auf Wallstreet Online.